Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia

Shots:

• Udenyca’s (Pegfilgrastim biosimilar) EU approval is based on the data demonstrating its PK and PD, for reducing the chances of infection by febrile neutropenia
• This biosimilar is currently under the US FDA inspection and has provided a PDUFA date 3 Nov, 2018. Udenyca is currently not available for commercial sale
• Udenyca (pegfilgrastim-cbqv/CHS-1701), is a growth-colony-stimulating-factor and a long-acting form of filgrastim that stimulates the production of WBCs and stem cells

Click here to read full press release/ article | Ref: Coherus Biosciences | Image: Stocks News Feed